With Shire's $1.6B Buyout, TKT On 'Verge Of Becoming Great'
It seemed bound to happen.
Getting ready to sign a partner in Europe for Dynepo (epoetin delta), its version of erythropoietin, Transkaryotic Therapies Inc. had been bracing an eager market for data from the pivotal Phase III trial with another therapy - iduronate-2-sulfatase for Hunter syndrome, expected in the second half of 2005, with Phase I/II data due about the same time from the open-label Phase I/II trial testing of yet another enzyme-replacement therapy, GA-GCB in Gaucher's disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter